secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0001193125-22-168878
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CEO Manuel Aivado appointed principal financial officer after CFO Richard Wanstall resigns
--------------------------------------------------------------------------------

- CFO Richard J. Wanstall resigned effective May 6, 2022.
- On June 5, 2022, CEO Manuel Aivado appointed as principal financial and accounting officer.
- Dr. Aivado has served as President and CEO since September 2018; no arrangement or family relationships.
- No transactions disclosed between Aivado and company per Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/0001193125-22-168878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522168878/d323390d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-168878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer